Ronald Tutrone

3.2k total citations · 2 hit papers
111 papers, 1.7k citations indexed

About

Ronald Tutrone is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ronald Tutrone has authored 111 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 28 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ronald Tutrone's work include Prostate Cancer Treatment and Research (85 papers), Prostate Cancer Diagnosis and Treatment (33 papers) and Hormonal and reproductive studies (28 papers). Ronald Tutrone is often cited by papers focused on Prostate Cancer Treatment and Research (85 papers), Prostate Cancer Diagnosis and Treatment (33 papers) and Hormonal and reproductive studies (28 papers). Ronald Tutrone collaborates with scholars based in United States, Canada and France. Ronald Tutrone's co-authors include Neal D. Shore, Daniel R. Saltzstein, Johan Skog, Michael S. Cookson, Michael Donovan, Mikkel Noerholm, Phillipp Torkler, Fred Saad, Vasisht Tadigotla and Bertrand Tombal and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Ronald Tutrone

102 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

2020 259 citations Neal D. Shore, Fred Saad et al. profile →
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

2023 114 citations Stephen J. Freedland, Martin Gleave et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ronald Tutrone United States	21	1.1k	426	398	309	295	111	1.7k
Robert Given United States	19	1.7k 1.6×	262 0.6×	474 1.2×	214 0.7×	268 0.9×	57	2.2k
Yong Mee Cho South Korea	22	807 0.7×	687 1.6×	288 0.7×	225 0.7×	206 0.7×	100	1.8k
Koji Mitsuzuka Japan	22	761 0.7×	424 1.0×	214 0.5×	101 0.3×	128 0.4×	117	1.5k
Debra J. Bruzek United States	16	1.1k 1.0×	321 0.8×	166 0.4×	76 0.2×	203 0.7×	34	1.4k
Eric N.P. Subong United States	13	1.3k 1.1×	383 0.9×	135 0.3×	184 0.6×	81 0.3×	19	1.8k
William J. Catalona United States	7	2.2k 1.9×	361 0.8×	193 0.5×	192 0.6×	84 0.3×	7	2.5k
Michiyuki Usami Japan	21	962 0.9×	268 0.6×	163 0.4×	76 0.2×	182 0.6×	89	1.3k
Charlotte Becker Sweden	25	1.0k 0.9×	355 0.8×	216 0.5×	36 0.1×	156 0.5×	46	1.7k
Darrel Drachenberg Canada	19	773 0.7×	438 1.0×	213 0.5×	239 0.8×	55 0.2×	99	1.5k
J Bellmunt Spain	14	967 0.9×	330 0.8×	434 1.1×	90 0.3×	57 0.2×	31	1.9k

Countries citing papers authored by Ronald Tutrone

Since Specialization

Citations

This map shows the geographic impact of Ronald Tutrone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Tutrone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Tutrone more than expected).

Fields of papers citing papers by Ronald Tutrone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Tutrone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Tutrone. The network helps show where Ronald Tutrone may publish in the future.

Co-authorship network of co-authors of Ronald Tutrone

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Tutrone. A scholar is included among the top collaborators of Ronald Tutrone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Tutrone. Ronald Tutrone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Calais, Jérémie, Michael J. Morris, A. Tuba Kendi, et al.. (2024). Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 65(11). 1666–1671. 5 indexed citations

Spratt, Daniel E., Daniel J. George, Neal D. Shore, et al.. (2024). Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncology. 10(5). 594–594. 4 indexed citations

Tutrone, Ronald, Fred Saad, Daniel J. George, et al.. (2023). Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. European Urology Oncology. 7(4). 906–913. 6 indexed citations

N., Kim, Neil Fleshner, Vincenzo Emanuele Chiurì, et al.. (2023). Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results. The Oncologist. 28(5). e309–e312. 11 indexed citations

Tutrone, Ronald, Michael Donovan, Yiyuan Yao, et al.. (2023). ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis. Prostate Cancer and Prostatic Diseases. 26(3). 596–601. 33 indexed citations

Freedland, Stephen J., Martin Gleave, Antti Rannikko, et al.. (2023). 1766MO Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study. Annals of Oncology. 34. S955–S955. 1 indexed citations

George, Daniel J., Fred Saad, Michael S. Cookson, et al.. (2023). Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. Clinical Genitourinary Cancer. 21(3). 383–392.e2. 6 indexed citations

Markowski, Mark C., Ronald Tutrone, Christopher Pieczonka, et al.. (2022). A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent. Clinical Cancer Research. 28(13). 2789–2795. 28 indexed citations

Stein, Mark N., Lawrence Fong, Ronald Tutrone, et al.. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist. 27(6). 453–461. 28 indexed citations

10.

Kretschmer, Alexander, Ronald Tutrone, Jason Alter, et al.. (2022). Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome. World Journal of Urology. 40(4). 983–989. 29 indexed citations

11.

Dixon, Christopher, Richard Levin, Christopher H. Cantrill, et al.. (2022). Transurethral Vapor Ablation in Patients with Intermediate-Risk Localized Prostate Cancer. Journal of Endourology. 37(2). 225–232. 2 indexed citations

12.

Brown, Gordon, Alan W. Partin, Ballentine Carter, et al.. (2021). Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer and Prostatic Diseases. 25(2). 296–301. 66 indexed citations

13.

Bossi, Alberto, Neal D. Shore, Ronald Tutrone, et al.. (2021). 622P Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC). Annals of Oncology. 32. S660–S660.

14.

Rukstalis, Daniel B., Sean P. Stroup, Ronald Tutrone, et al.. (2018). Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer and Prostatic Diseases. 22(3). 411–419. 74 indexed citations

15.

Neste, Leander Van, Kelvin A. Moses, Jonathan Silberstein, et al.. (2018). Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men. Urology. 128. 62–65. 26 indexed citations

16.

Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2017). Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clinical Cancer Research. 23(14). 3544–3551. 64 indexed citations

17.

Shore, Neal D., Elisabeth I. Heath, Luke T. Nordquist, et al.. (2017). Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Annals of Oncology. 28. v272–v272. 1 indexed citations

18.

Shenoy, B. Vittal, Ronald Tutrone, Lawrence I. Karsh, et al.. (2017). Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer and Prostatic Diseases. 21(1). 78–84. 47 indexed citations

19.

Yu, Evan Y., Robert H. Getzenberg, Christopher C. Coss, et al.. (2014). Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. European Urology. 67(2). 334–341. 16 indexed citations

20.

Staskin, David, Tamara Bavendam, Jane L. Miller, et al.. (1996). Effectiveness of a urinary control insert in the management of stress urinary incontinence: early results of a multicenter study. Urology. 47(5). 629–636. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact